Natriumklorid Viaflo Baxter (Sodium Chloride)

When infused, sodium chloride dissociates into sodium and chloride ions, raising extracellular sodium concentration and osmolarity. The increased osmotic pressure draws water from the intracellular and interstitial spaces into the bloodstream, expanding plasma volume and helping to normalize electrolyte gradients essential for nerve, muscle, and renal function.

The dose of Natriumklorid Viaflo Baxter is determined by the prescribing clinician based on the patient’s specific fluid and electrolyte needs, underlying condition, and clinical response. No fixed regimen is provided; the healthcare professional calculates the appropriate volume and rate of infusion for each individual case.

Safety data for Natriumklorid Viaflo Baxter in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Natriumklorid Viaflo Baxter is an isotonic sodium chloride injection comparable to other 0.9% NaCl solutions. Its clinical performance is similar, but differences may exist in packaging, sterility assurance, and regulatory compliance. GNH India’s offering is sourced from EU manufacturers and adheres to GDP standards, which can be advantageous for international procurement.

The product should be stored at 2‑8 °C (refrigerated). Keep it in the original container, protect it from light, and avoid freezing or shaking the vial. If the solution appears cloudy or contains particles, it should not be used.

It is administered intravenously, either as a slow infusion or a rapid bolus, depending on the clinical situation. The infusion rate is set by the prescriber and should be monitored continuously for signs of fluid overload, changes in blood pressure, or electrolyte disturbances.

Serious risks include severe hypernatremia, fluid overload leading to pulmonary edema or heart failure, and rare anaphylactic reactions. Prompt recognition of symptoms such as sudden shortness of breath, chest pain, rash, or a rapid rise in serum sodium is essential for immediate medical intervention.

Patients with known hypersensitivity to sodium chloride solutions, those with existing severe hypernatremia, uncontrolled heart failure, or severe fluid overload should not receive this product. Clinicians should also exercise caution in patients with renal impairment or those receiving concurrent hypertonic saline.